aTYR PHARMA INC (ATYR) research
aTYR PHARMA INC- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $0.29
- As of
aTYR PHARMA INC (ATYR): 5 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-09-24.
As of . Source: SEC EDGAR filings for ATYR. Method and limitations.
Share the ATYR intelligence card
See the full ATYR dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for ATYR on one page. Preview it with sample data, then open it live with a free account.
Preview the ATYR dossierActive signals for ATYR
- highCONSENSUS_BUY
4 tracked funds increased ATYR this 2026Q2, institutional consensus
- mediumNEW_POSITION
Point72 Asset Management, L.P. new position in ATYR
- highINSTITUTIONAL_EXIT
MILLENNIUM MANAGEMENT LLC cut 60% of ATYR (2026Q2)
- highINSTITUTIONAL_SURGE
RENAISSANCE TECHNOLOGIES LLC added +308% to ATYR (2026Q2)
- highINSTITUTIONAL_EXIT
CITADEL ADVISORS LLC cut 77% of ATYR (2026Q2)
FREE, NO ACCOUNT
Every signal on ATYR, as it fires
You are seeing 5 of 13 signals recorded on ATYR since 2026-05-31.
The five above landed across 2 days. The other 8 were recorded on 3 other days. 7 of the 13 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in ATYR (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| TWO SIGMA INVESTMENTS, LPCUSIP 002120202 · 2026Q2 | $743K | 0.00% | , |
| CITADEL ADVISORS LLCCUSIP 002120202 · 2026Q2 | $741K | 0.00% | , |
| MILLENNIUM MANAGEMENT LLCCUSIP 002120202 · 2026Q2 | $392K | 0.00% | , |
| RENAISSANCE TECHNOLOGIES LLCCUSIP 002120202 · 2026Q2 | $99K | 0.00% | , |
| Point72 Asset Management, L.P.CUSIP 002120202 · 2026Q2 | $22K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, ATYR
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
ATYR against its peers
ATYR's operating margin of -40856.3% ranks in the 6th percentile of 8 Biotechnology sub-industry peers, fiscal periods ending between 2025-09-30 and 2025-12-31.
| Metric | ATYR | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 190000 USD | 789000 USD | 25 | 9 |
| Operating margin | -40856.3% | -1489.3% | 6 | 8 |
| Net margin | -39009.5% | -768.1% | 6 | 8 |
| Return on equity | -109.8% | -80.3% | 42 | 12 |
Peers (16): RNAZ, QNCX, CVM, CNTX, BRNS, ABVC, KYNB, SGMO, LONA, PSTV, HOTH, GNTA, GRDX, ALGS, MCRB, PVCT. Left out: EVAX (no annual filing), IGC (no annual filing), CLCS (period gap), MDNAF (no annual filing), TTIPF (no annual filing), QNTM (no annual filing), VICP (period gap), PLRZ (no annual filing), SEOVF (no annual filing). Fiscal periods ending between 2025-09-30 and 2025-12-31. Every figure is one full fiscal year read from one annual filing (ATYR: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
See more ATYR signals as they fire
Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to ATYRand get the insider, 13F, options, and confluence read in one view.